Skip to main content Skip to main menu
UF Health University of Florida
Division of Hematology & Oncology Department of Pediatrics in the College of Medicine
Giselle J Moore-Higgs

Giselle J Moore-Higgs, APRN, PhD

Associate Director, Clinical Research

Department: MD-PEDS-HEMATOLOGY
Business Phone: (352) 273-9050
Business Email: mooregj@ufl.edu

On This Page

Publications

Academic Articles

Grants

  1. A Phase Ib/II Study to Evaluate the Safety, Feasibility and Efficacy of Nivolumab or Nivolumab in Combination with Azacitidine in Patients with Recurrent, Resectable Osteosarcoma

    Active

    Role:
    Other
    Funding:
    H LEE MOFFITT CANCER CTR & RES INST via FL DEPT OF HLTH LIVE LIKE BELLA

  2. A Phase Ib/II Study to Evaluate the Safety, Feasibility and Efficacy of Nivolumab or Nivolumab in Combination with Azacitidine in Patients with Recurrent, Resectable Osteosarcoma

    Role:
    Other
    Funding:
    H LEE MOFFITT CANCER CTR & RES INST via FL DEPT OF HLTH

  3. A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (IND#:133494, NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy (NCORP funding)

    Active

    Role:
    Project Manager
    Funding:
    CHILDRENS ONCOLOGY GROUP via NATL INST OF HLTH NCI

  4. A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (IND#:133494, NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy (NCTN funding)

    Active

    Role:
    Project Manager
    Funding:
    CHILDRENS ONCOLOGY GROUP via NATL INST OF HLTH NCI

  5. A Phase IV, Multicenter, Single-Arm, Open-Label Study of Emicizumab Prophylaxis in Patients With Hemophilia A and Inhibitors Undergoing Minor Surgical Procedures

    Role:
    Other
    Funding:
    PHARMACEUTICAL RES ASSO via GENENTECH INC

  6. Prospective, Multinational, Non-interventional Post-authorisation Study to Document the Long-term Immunogenicity, Safety, and Efficacy of Human-cl rhFVIII (Simoctocog Alfa) in Patients With Haemophilia A Treated in Routine Clinical Practice

    Role:
    Other
    Funding:
    Octapharma USA

Contact Details

Phones:
Business:
(352) 273-9050
Emails:
Business:
mooregj@ufl.edu
Addresses:
Business Mailing:
1600 SW ARCHER ROAD, HD-204
1600 SW ARCHER RD # HD-204
PEDIATRIC HEMATOLOGY ONCOLOGY
 GAINESVILLE FL 32610
Business Street:
DEPARTMENT OF PEDIATRIC HEMATOLOGY ONCOLOGY
1600 SW ARCHER RD RM MSB-351
 GAINESVILLE FL 32610